FDA DEVICE FACTS
Lung AI (LAI001)
Exo Inc
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
Lung AI software device is a Computer-Aided Detection (CADe) tool designed to assist in the detection of consolidation/atelectasis and pleural effusion during the review of lung ultrasound scans. The software is an adjunctive tool to alert users to the presence of regions of interest (ROI) with consolidation/atelectasis and pleural effusion within the analyzed lung ultrasound cine clip. Lung AI is intended to be used on images collected from the PLAPS point, in accordance with the BLUE protocol. The intended users are healthcare professionals who are trained and qualified in performing lung ultrasound and routinely perform lung ultrasounds as part of their current practice in a point-of-care environment—namely Emergency Departments (EDs). The device was not designed and tested with use environments representing EMTs and military medics. Lung AI is not intended for clinical diagnosis and does not replace the healthcare provider's judgment or other diagnostic tests in the standard care for lung ultrasound findings. All cases where a Chest CT scan and/or Chest X-ray is part of the standard of care should undergo these imaging procedures, irrespective of the device output. The software is indicated for adults only.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。